FDA Approves Shionogi's Xocova for COVID-19 Prevention
The FDA approved Shionogi's Xocova to prevent COVID-19 after exposure regardless of vaccination status. The move is reflected in current earnings forecasts.
SHIONOGI & CO LTD received FDA approval for its oral antiviral Ensitrelvir to prevent COVID-19 infections following exposure. The drug, marketed as Xocova, is the first oral preventive treatment clinically proven effective regardless of a patient's vaccination status. The approval secures a critical foothold for the Osaka-based pharmaceutical firm in the United States healthcare market.
### First-of-Its-Kind Preventive Treatment The FDA cleared Ensitrelvir for individuals exposed to the virus to stop symptomatic development. Nathan McCutcheon, CEO of the U.S. unit of Shionogi, stated that the drug is the only oral option proven to help prevent symptomatic COVID-19 after exposure. This clinical milestone differentiates the product from existing treatments that focus primarily on post-infection recovery.
